Timolol external preparation for treating hemangioma

A technology for external preparations and hemangioma, which is applied in the field of pharmaceutical preparations, can solve the problems of inflow into the eye, systemic adverse reactions, and volatile solutions, and achieves the effects of convenient application, small adverse reactions, and simple and easy process.

Inactive Publication Date: 2016-10-12
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the solution is volatile and has a short action time. When it is applied to the lesions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Timolol external preparation for treating hemangioma
  • Timolol external preparation for treating hemangioma
  • Timolol external preparation for treating hemangioma

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0026] The preparation method of the above-mentioned external preparation for treating hemangioma comprises the following steps:

[0027] (1) Timolol is prepared in a salt form into a timolol salt solution, and the concentration of the timolol salt solution is 0.1% to 90%;

[0028] (2) adding the active ingredient peppermint oil of formula quantity in step (1) gained timolol salt solution;

[0029] (3) Add an appropriate amount of preservative, humectant, antioxidant to the solution obtained in step (2), and stir evenly;

[0030] (4) disperse the solution obtained in step (3) in the gel matrix according to the weight ratio of 1:1 to 1:10, and swell to obtain the timolol gel;

[0031] The solution obtained in step (3) is dispersed in the ointment base according to the weight ratio of 2.5:1 to 3:1 to obtain timolol ointment.

[0032] Wherein, the preservative is selected from one of ethylparaben, butylparaben, chlorobutanol, sodium benzoate and sorbic acid.

[0033] The humec...

Embodiment 1

[0038] Prescription (percentage by weight):

[0039]

[0040]

[0041] Preparation Process:

[0042] (1) get timolol maleate and sodium bisulfite of prescription quantity, accurately weighed, be dissolved in 10ml water, make aqueous phase;

[0043] (2) Add carbomer to the remaining water and stir, and add sodium hydroxide as a pH regulator to adjust the pH to 7-8 to make it fully swell to obtain a gel matrix;

[0044] (3) Add the aqueous phase obtained in step (1) into the gel matrix, and add peppermint oil, sodium benzoate, propylene glycol, etc., to obtain an external gel for treating hemangioma.

Embodiment 2

[0046] Prescription (percentage by weight):

[0047] timolol maleate

0.5g

peppermint

1g

sodium alginate

2.5g

Sorbic acid

0.5g

sodium bisulfite

0.3g

glycerin

2g

water

Add to 100g

[0048] Preparation Process:

[0049] (1) get timolol maleate and sodium bisulfite of prescription quantity, accurately weighed, be dissolved in 20ml water;

[0050] (2) adding sodium alginate to the remaining water, stirring overnight to make it fully swell to obtain a gel matrix;

[0051] The aqueous phase obtained in the step (1) is added into the gel matrix, and peppermint oil, sorbic acid, glycerin and the like are added to obtain the external gel for treating hemangioma.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a timolol external preparation for treating hemangioma. The prepared external preparation is ointment or gel prepared in the mode that two active ingredients including timolol and oleum menthae are added into a gel matrix or an ointment matrix, wherein the content of the timolol, by mass, accounts for 0.25-1% of the ointment or the gel, and the content of the oleum menthae, by mass, accounts for 1% of the ointment or the gel. The preparation method comprises the steps that timolol is prepared into a timolol saline solution in a salifying mode, the active ingredient oleum menthae is added into the timolol saline solution, the obtained solution is dispersed into the gel matrix according to the weight ratio of (1:1)-(1:10) to be subjected to swelling, and the gel is obtained; or the obtained solution is dispersed into the ointment matrix according to the weight ratio of (2.5:1)-(3:1), and the ointment is obtained. The preparation process is simple, easy to practice and applicable to requirements of industrial mass production. Pharmacodynamics results prove that the effective ingredients timolol and oleum menthae in the external preparation have the synergism for treating hemangioma and good tolerance, and no adverse reaction occurs.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an external timolol preparation for treating hemangioma and a preparation method thereof. Background technique [0002] Infantile hemangioma is the most common benign tumor in infants and young children, with an incidence rate as high as 10% and a tendency to increase year by year. More than 60% occur on the face and head and neck. Prematurity and low birth weight (<1500g) are possible predisposing factors, as is the use of progesterone during pregnancy. Clinically, it presents as erythematous patches of telangiectasia, papules, hypertrophic plaques, and masses. Although hemangiomas can regress on their own, some children still have serious complications such as ulcers, infections, pain, and even blindness and suffocation. [0003] After the β-receptor blocker propranolol was used to treat infantile hemangioma, it quickly became the first-line drug, but with a lar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/534A61K9/06A61P35/00A61K31/5377
CPCA61K31/5377A61K9/0014A61K9/06A61K36/534A61K47/02A61K47/36A61K47/44A61K2300/00
Inventor 高琳王晓娟赵慧雯王刚李凯李朝阳周晨曦
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap